Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    thumbnail
    Making sense of the rapidly changing biosimilars landscape

    Strategies for adapting and achieving optimal market access

    thumbnail
    Building a comparative evidence base using network meta-analysis

    Methods, implementation and reporting

    FSA_thumbnail
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    oligonucleotides
    Insights into first-in-human study design of oligonucleotides

    27 May 2026. Register now.

    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Healthy participants Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

ICON Plc facebook post
ICON Plc logo
ICON Plc

Although biosimilars play an important role in improving cancer treatment accessibility, many patients and providers hold misconceptions or doubts about them. Learn how oncology biosimilar developers can encourage uptake...

28 Oct
2
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Although biosimilars play an important role in improving cancer treatment accessibility, many patients and providers hold misconceptions or doubts about them. Learn how oncology biosimilar developers can encourage uptake...

28 Oct
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Technology is the backbone of modern risk-based quality monitoring. ICON’s latest blog explores how central monitoring, predictive analytics and system-agnostic platforms enable earlier risk detection and more efficient ...

28 Oct
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Technology is the backbone of modern risk-based quality monitoring. ICON’s latest blog explores how central monitoring, predictive analytics and system-agnostic platforms enable earlier risk detection and more efficient ...

28 Oct
3
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Attending #ACR25? Meet ICON experts at booth \#1501 to learn how our tailored strategies, delivered with flexibility and deep therapeutic expertise, can help you drive success in your clinical trial.  https://lnkd.in/eHf...

27 Oct
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Historically, high development costs and complex approval processes have been an impediment to #biosimilar development. There is an urgent need to promote changes in how regulators assess biosimilars, as well as to ide...

27 Oct
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Historically, high development costs and complex approval processes have been an impediment to biosimilar development. There is an urgent need to promote changes in how regulators assess biosimilars, as well as to identi...

27 Oct
3
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Proven success in early phase obesity studies. See how ICON streamlined an early phase obesity study with tailored recruitment, participant-centric support, and operational excellence to reduce dropout rates and ensure c...

27 Oct
2
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

From fragmented regulations to limited GMP capacity, APAC presents unique challenges for CGT sponsors. ICON experts share how strategic alliances and tech innovation are reshaping the landscape. Read more https://ow.ly/u...

27 Oct
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

As the Asia-Pacific (APAC) region continues to emerge as a key player in the biosimilar sector, it presents significant opportunity for market entry and expansion. In our latest blog on this region, we explore critical...

27 Oct
1
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

As the Asia-Pacific (APAC) region continues to emerge as a key player in the biosimilar sector, it presents significant opportunity for market entry and expansion. In our latest blog on this region, we explore critical...

27 Oct
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Your partner in cardiovascular device development. Our global team of experts—including interventional cardiologists, electrophysiologists, and statisticians—delivers integrated solutions for every stage of your device l...

27 Oct
View post
View webpage
  • Previous
  • 1
  • …
  • 67
  • 68
  • 69
  • …
  • 100
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies